FCGR2B 232I/T transformed to FCGR2B 232T making FcγRIIB unable to interact with activating receptors and exert inhibitory effect [14] which accounts for the role of FCGR2B 232I/T and FcγRIIB in development of CM. Here, FCGR2B is linked to cutaneous mastocytosis.